We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$11.1B
1-Year Est. Return
207.82%
This Fund
S&P 500
This Quarter
Est. Return
+42.24%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$2.31B
AUM Growth
+$640M
(+38%)
Cap. Flow
+$31.4M
Cap. Flow
% of AUM
1.36%
Top 10 Holdings %
Top 10 Hldgs %
73.01%
Holding
40
New
6
Increased
6
Reduced
12
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$46.1M |
| 2 |
AMRN
Amarin Corp
AMRN
|
+$43.7M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$41.6M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$36.8M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$30.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$63.6M |
| 2 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$45.5M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$22.2M |
| 4 |
TG Therapeutics
TGTX
|
+$19.5M |
| 5 |
Ascendis Pharma A/S
ASND
|
+$16.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.95% |
| 2 | Miscellaneous | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMMU
1
DELISTED
Immunomedics Inc
IMMU
| $340M | 14.71% |
17,714,461
| – | – |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $283M | 12.24% |
3,862,500
-935,601
| -19% | -$63.6M |
|
|
3
Ascendis Pharma A/S
ASND
$15.2B
| $211M | 9.14% |
1,795,000
-185,000
| -9% | -$16.2M |
|
|
AMRN
4
Amarin Corp
AMRN
$293M
| $166M | 7.18% |
400,000
+121,250
| +43% | +$43.7M |
|
5
Sarepta Therapeutics
SRPT
$2.19B
| $142M | 6.16% |
1,195,000
-80,000
| -6% | -$10.3M |
|
|
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
| $129M | 5.59% |
9,500,000
-625,000
| -6% | -$7.63M |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $106M | 4.57% |
4,000,000
-350,000
| -8% | -$8.29M |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $105M | 4.56% |
1,915,000
-60,000
| -3% | -$2.85M |
|
9
argenx
ARGX
$62.3B
| $105M | 4.53% |
840,000
-20,000
| -2% | -$2.35M |
|
10
Iovance Biotherapeutics
IOVA
$4.17B
| $100M | 4.33% |
10,530,862
+269,823
| +3% | +$2.62M |
|
|
11
BioMarin Pharmaceuticals
BMRN
$12.4B
| $99.5M | 4.3% |
1,120,000
-240,000
| -18% | -$22.2M |
|
|
TCDA
12
DELISTED
Tricida, Inc. Common Stock
TCDA
| $65.7M | 2.84% |
1,700,000
-50,000
| -3% | -$1.16M |
|
|
MYOK
13
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $52M | 2.25% |
+1,000,000
| New | +$46.1M |
|
|
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $50.3M | 2.17% |
950,000
+600,000
| +171% | +$29.5M |
|
|
ARRY
15
DELISTED
Array Biopharma Inc
ARRY
| $48.8M | 2.11% |
+2,000,000
| New | +$41.6M |
|
|
MDCO
16
DELISTED
Medicines Co
MDCO
| $43.7M | 1.89% |
+1,562,000
| New | +$36.8M |
|
|
BDSI
17
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $39.4M | 1.7% |
7,424,867
+2,699,867
| +57% | +$12.3M |
|
18
Madrigal Pharmaceuticals
MDGL
$11.9B
| $38.8M | 1.68% |
310,000
+85,000
| +38% | +$10.6M |
|
|
19
Acadia Pharmaceuticals
ACAD
$4.62B
| $35.6M | 1.54% |
+1,325,000
| New | +$30.9M |
|
20
Allogene Therapeutics
ALLO
$601M
| $29.8M | 1.29% |
1,128,594
+10
| +0% | +$290 |
|
21
Xenon Pharmaceuticals
XENE
$5.5B
| $24.4M | 1.05% |
2,400,000
| – | – |
|
22
Indaptus Therapeutics
INDP
$468M
| $18.3M | 0.79% |
1,116
| – | – |
|
23
Assembly Biosciences
ASMB
$548M
| $17.7M | 0.77% |
75,000
-8,333
| -10% | -$2.11M |
|
24
Pacira BioSciences
PCRX
$951M
| $15.2M | 0.66% |
400,000
| – | – |
|
25
Establishment Labs
ESTA
$2.14B
| $11.4M | 0.49% |
475,000
| – | – |
|
Similar funds
GI
AIM
BEI
VNIM
MF
MC
GJL
LCAM
Avoro Capital Advisors's Q1 2019 Portfolio in Review
As of Q1 2019, Avoro Capital Advisors held 40 positions worth $2.31B, up 38% from $1.67B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Avoro Capital Advisors's Q1 2019 filing shows 6 new, 6 increased, 12 reduced and 8 closed positions. Its largest new stake was MyoKardia, Inc. Common Stock: 1,000,000 shares worth $52M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $63.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Avoro Capital Advisors's largest Q1 2019 buy was MyoKardia, Inc. Common Stock: 1,000,000 shares worth $52M.
- Avoro Capital Advisors added most to Amarin Corp in Q1 2019, an estimated $43.7M increase.
- Avoro Capital Advisors's biggest Q1 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $63.6M.
- Avoro Capital Advisors fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $45.5M.
- Avoro Capital Advisors's ten largest holdings make up 73% of its $2.31B portfolio in Q1 2019.
- Avoro Capital Advisors opened 6 new positions and closed 8 in Q1 2019.
- Avoro Capital Advisors's portfolio value rose 38% quarter-over-quarter to $2.31B.
Based on Avoro Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.